Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Multicenter, Multi-cohort Phase II Clinical Trial of Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.

NCT06857747 is registered in ClinicalTrials.gov with QIAO LI as lead sponsor.

NCT NCT06857747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06857747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Multicenter, Multi-cohort Phase II Clinical Trial of Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.
Lead sponsor
QIAO LI
Phase
Not applicable
Overall status
Unknown status
Start date
March 1, 2025
Completion date
April 1, 2026
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer